Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.
about
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sicknessSCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In VitroPredicting binding to p-glycoprotein by flexible receptor dockingHuman Brain Microvascular Endothelial Cells Derived from the BC1 iPS Cell Line Exhibit a Blood-Brain Barrier PhenotypeHighly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 miceChallenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.Methods to assess drug permeability across the blood-brain barrier.Towards Better BBB Passage Prediction Using an Extensive and Curated Data Set.Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols.New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it?Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A.Brainpeps: the blood-brain barrier peptide database.The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathiesChallenges for blood-brain barrier (BBB) screening.A new in situ brain perfusion flow correction method for lipophilic drugs based on the pH-dependent Crone-Renkin equation.TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugsNovel method to label solid lipid nanoparticles with 64cu for positron emission tomography imaging.Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins.Use of biopartitioning micellar chromatography and RP-HPLC for the determination of blood-brain barrier penetration of α-adrenergic/imidazoline receptor ligands, and QSPR analysis.Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization.Improving the prediction of the brain disposition for orally administered drugs using BDDCS.Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein.Alternating magnetic field-induced hyperthermia increases iron oxide nanoparticle cell association/uptake and flux in blood-brain barrier models.Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines.Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.Analytical and biological methods for probing the blood-brain barrier.Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin.Mitigating permeability-mediated risks in drug discovery.In vitro, in vivo and in silico models of drug distribution into the brain.Strategies to assess blood-brain barrier penetration.Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.Overview of experimental models of the blood-brain barrier in CNS drug discovery.
P2860
Q21144517-4FFDAB7E-CF78-4AB5-9A5E-CDC123E97324Q27490844-8B164C68-E4E7-440E-ADEC-514E2E27C105Q28478693-37B373B0-B0F9-4603-BFEF-4EF032CF67B9Q28551318-E05543AF-3320-4439-B290-EC1867E00CCDQ30540417-F8C9A185-B54B-4C75-83C6-80AD94281113Q30651426-B3E37B71-3F1F-4B98-936D-3549952CE873Q31034258-387BE8DD-C694-4C8B-8A78-D74AAFB1A83CQ31119557-F6BE4294-F044-4F37-B7FF-8AF065161A53Q33530732-E111FEB3-BDC2-4DD8-A7D2-F8936A4CA1E4Q33792474-F22F696A-17FF-497C-B03E-31B57CF852B6Q33946973-FB6D160E-6C41-443C-A395-E59A76462572Q33995372-0F83CC2B-5596-4357-96EE-EB3CDA69A5CFQ34083438-7FD10AAF-EFC9-4203-8449-92DDB7BD989EQ34243408-88EA9C99-DCE9-4F25-8914-F0F368AA932DQ34587678-D1DC1D9B-267E-4F85-8EBE-E51C4EBB5610Q34707666-7838E83F-71B6-4A47-BDD7-D707075D6E5BQ34789397-8C4F55B4-5E60-49EB-BCC6-4C3E9D77F6A3Q34818171-57338B99-F82E-4107-9F1B-96942D9580CFQ34906375-67ACE492-5B15-4C5D-B9B0-5E2B327FCF32Q35057548-1B6A36B7-FA56-4D0E-84E7-3E0C4A3467EFQ35715564-3D704C10-4EB8-4A92-BE12-4E92515AED10Q36276693-047569BE-1E9B-47F9-ABD0-53311CB3AE63Q36316489-9FA76DAD-6048-426C-B642-43FFBCF1C312Q36319277-07D72232-8018-4416-A6E3-4C80352DC862Q36344515-1519BB0D-CACF-4F5B-982A-B404076C9759Q36394062-7F03B1E3-CCB1-4E39-B11F-C6FD757496EBQ36691249-3B02D740-D995-4C4C-9ECD-0F9741D14288Q36715672-76FF8913-5845-474E-AEEF-BF35C056ED8DQ36733346-123147FF-11C2-44F1-A2AF-3164608A3A79Q36744766-09088143-61E2-4AB6-A5D8-9E1A67FEF96BQ36755346-93763720-E3F7-4900-BBB4-011D4833B30AQ37096694-4D6DF398-37ED-4A17-98C1-402A78038AEEQ37284843-AACC7365-DB94-43EA-B90F-9749B574682DQ37286215-92C7DD65-3E35-49D6-949A-7E9EE4C7813EQ37418045-F35F75A2-E234-4A3F-A06D-148F88D14B2DQ37671826-9AEAE128-D2BA-434C-BDBB-C73D15A47DAFQ38081102-B33D20B8-D969-4527-B2F5-64C0AC00E506Q38090672-EE2362DA-4920-46B7-B012-4B8526EB02D5Q38117056-34B956B8-11F5-4AA3-9F6A-B276DA34043DQ38186650-9CB4CD85-FDFC-48A3-A1A0-72E2D71DEC5F
P2860
Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Evaluation of the MDR-MDCK cel ...... n for the blood-brain barrier.
@en
type
label
Evaluation of the MDR-MDCK cel ...... n for the blood-brain barrier.
@en
prefLabel
Evaluation of the MDR-MDCK cel ...... n for the blood-brain barrier.
@en
P2093
P1476
Evaluation of the MDR-MDCK cel ...... n for the blood-brain barrier.
@en
P2093
Glenn L Dobson
Ismael J Hidalgo
Joseph D Rager
Kathryn Weinstein
Paula S Kardos
P304
P356
10.1016/J.IJPHARM.2004.10.007
P407
P577
2004-12-15T00:00:00Z